January 8, 2018 / 1:41 PM / 5 months ago

BRIEF-Xenon Pharmaceuticals Expects To Have Ongoing XEN1101 Phase 1 Clinical Trial Completed By Mid-Year

Jan 8 (Reuters) - Xenon Pharmaceuticals Inc:

* XENON PHARMACEUTICALS OUTLINES KEY MILESTONES FOR 2018

* XENON PHARMACEUTICALS INC - EXPECT TO HAVE ONGOING XEN1101 PHASE 1 CLINICAL TRIAL COMPLETED BY MID-YEAR

* XENON PHARMACEUTICALS INC - IN SECOND HALF OF THIS YEAR, ANTICIPATE HAVING COMPLETED XEN901 PHASE 1 CLINICAL TRIAL

* XENON PHARMACEUTICALS INC - ANTICIPATE THAT BOTH XEN1101 AND XEN901 COULD BE IN PHASE 2 DEVELOPMENT BY END OF THIS YEAR

* XENON PHARMACEUTICALS INC - AS OF DECEMBER 31, 2017, CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $43.7 MILLION

* XENON PHARMACEUTICALS INC - BASED ON CURRENT ASSUMPTIONS, XENON ANTICIPATES HAVING SUFFICIENT CASH TO FUND OPERATIONS INTO MID-2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below